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Summary 
DNA fragments coding for a variety of different viral antigens have been cloned and ex-
pressed in Escherichia coli. Selected purified recombinant antigens were used for detection of 
specific antibodies by means of the ELISA technique. This approach has been used for the de-
velopment of four different ELISAs for the detection of HIV- and EBV-specific antibodies. 
Introduction 
The majority of serological tests still uses not exactly defined natural 
antigens from different sources to detect virus-specific antibodies. Recom-
binant technology is in most cases the only alternative to produce selected vi -
ral antigens in large amounts in order to enhance sensitivity/specificity or fa-
cilitate standardized differential diagnosis. One of the major problems using 
recombinant proteins, however, is the identification of those antigens or frag-
ments which are useful in serological diagnosis. In the following we summa-
rize experiments which led to the development of two different recombinant 
test systems for the detection of HIV- and EBV-specific antibodies. 
Material and Methods 
Methods which led to the recombinant constructs mentioned here as well as methods 
used for evaluation in Western blot and ELISA experiments have been described in detail pre-
viously [1-4). 
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Results and Discussion 
Evaluation of Recombinant HIV Antigens 
In order to evaluate the diagnostic potential of different HIV antigens 
D N A fragments of all HIV-1 reading frames were cloned and expressed in 
Escherichia coli. Selected clones were evaluated in Western blot experi-
ments with more than 400 different sera of HIV-infected, exactly classified 
individuals including 9 seroconversion panels. Results obtained with two dif-
ferent panels of patients of different clinical stages are summarized in table 
1. The only antigen which reacted with all sera was gp41/l representing the 
N-terminal region of the transmembrane protein. High reactivity was also 
obtained with recombinant p66 (reverse transcriptase) and p31 (integrase), 
while seroprevalence rates of the G A G antigens p24 and p i 7 were lower and 
revealed a large heterogeneity. The same was true for the regulative proteins. 
The identification of antigens which are reactive during the seroconver-
sion period is also of major interest. Useful tools for the evaluation of reac-
tivity during seroconversion are seroconversion panels, which consist of 
longitudinal series of plasma samples collected from a single individual be-
fore, during and after seroconversion [5]. The N-terminal portion of the 
transmembrane protein (gp41/l) and p24 are the first reactive antigens while 
the other structural proteins are less important. 
In conclusion to our data gp41 and p24 are excellent antigens to ensure 
safe diagnosis in all stages of infection, while p66 and p31 are in addition 
good candidates for a recombinant confirmation assay. In very early stages of 
infection, however, reactivity with only one antigen, in general gp41, might 
be possible. In order to guarantee a safe serodiagnosis of HIV-2 infections we 
chemically synthesized a 492bp D N A fragment coding for the N-terminal re-
gion of HIV-2, and expressed the recombinant antigen in Escherichia coli. In 
E L I S A experiments the purified antigen revealed strong reactivity with all 
HIV-2-specific sera tested so far. Using the three different recombinant anti-
Table I. Seroreacti vity of recombinant antigens (%) in Western blot - total reactivity with two 
panels of sera of HIV-infected individuals 
n pi7 p24 p66 p3l gp!20 gp41/l gp41/2 nef vif tat rev vpu 
64 26 39 98 88 25 
58 44 71 98 79 43 
100 
100 
38 8 36 3 64 15 
56 34 7 9 41 31 
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gens gp41 and p24 (HIV-1) and gp35 (HIV-2) we were able to develop the 
Biotest HIV-1/-2 recombinant E L I S A , which reveals excellent sensitivity 
and specificity. 
Development of a New EBV-ELISA System Using Recombinant Antigens 
Approximately 90% of the adult population are infected by Epstein-
Barr virus (EBV) . Although primary infections with E B V are in general 
asymptomatic they lead, in some cases, to a clinical syndrome called infec-
tious mononucleosis (morbus Pfeiffer, kissing disease). E B V is also closely 
associated with two malignancies, i.e. nasopharyngeal carcinoma and Bur-
ki t f s lymphoma, and may be reactivated in immunosuppressed patients. 
There is also an increasing demand for EBV-negative blood in order to avoid 
complications in transplantation medicine. In previous studies recombinant 
antigens were identified which ensure a safe serological diagnosis in all 
types of E B V infection [3, 4, 6, 7]. These data led to the development of a set 
of three ELISAs; the technical data of the recombinant antigens and the com-
position of the different ELISAs are summarized in table 2. In several studies 
[4, 7, 8] this set of E B V-ELISAs has proven to be very useful for the diagno-
sis of all stages of E B V infection, and offers an excellent alternative to the 
time-consuming and not exactly standardized immunofluorescence techni-
Table 2. Recombinant EBV antigens and composition of Biotest anti-EBV ELISA 
Protein 
p54 pl38 p72 
Reading frame BMRF I B A L F 2 BKRF 1 







Construction Whole coding 
region 




Size of expression 
protein, kD 
52/47 39 46 
ELISA IgM • • 
EA IgG • • 
EBNA IgG • 
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ques which are routinely used in E B V diagnosis. In addition, the E L I S A 
system shows no interference with anticellular antibodies, and a general pre-
treatment of sera prior to evaluation of specific IgM antibodies in order to 
remove rheumatoid factors is not necessary. These findings show that the re-
combinant E B V - E L I S A s enable easy and standardized performance of E B V 
serodiagnosis. 
In general the preparation of viral antigens by the means of recombinant 
technology results in an improvement of sensitivity and specificity of serolo-
gical diagnosis of viral infections. Utilization of selected recombinant anti-
gens allows the safe identification of the different stages of viral infections. 
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